D. Ravi

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.

M. Tsao, O. Ludkovski, F. Shepherd, 2020, Lung cancer.

MTE01.02 Lung Patient Derived Xenograft and Organoid

M. Moran, M. Tsao, F. Shepherd, 2018, Journal of Thoracic Oncology.